Protocol Ledger

NCT03710876 · Phase III · COMPLETED

Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma

Interventional Phase III clinical trial protocol NCT03710876 sponsored by Ferring Ventures Limited in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-01-21 Enrollment: 53 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03710876
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)53 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03710876
Protocol FieldVerified Registry Value
NCT IdentifierNCT03710876
Consolidated Lead SponsorFerring Ventures Limited
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment53 participants (ACTUAL)
Registered Start Date2019-01-21
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI